Uluru Inc. (OTCMKTS:ULUR) is Attracting Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Uluru Inc. (OTCMKTS:ULUR) reported that Sacks Michael Ivan has picked up 43,711,970 of common stock as of 2017-04-13.
The acquisition brings the aggregate amount owned by Sacks Michael Ivan to a total of 43,711,970 representing a 48.4% stake in the company.
For those not familiar with the company, ULURU Inc. is a specialty pharmaceutical company focused on developing and commercializing a range of wound care and muco-adhesive film products based on its Nanoflex and OraDisc technologies for patients, healthcare professionals and healthcare payers. The Company operates through the research, development and commercialization of pharmaceutical products segment. Utilizing its technologies, three of its products have been approved for marketing in various global markets. Altrazeal Transforming Powder Dressing is based on its Nanoflex technology, which changes the way healthcare providers approach their treatment of wounds. The product is indicated for both exuding acute wounds, such as donor sites, non-healing surgical wounds, and trauma and for chronic wounds, such as venous leg ulcers, diabetic foot ulcers and pressure ulcers. Aphthasol is a drug approved for the treatment of canker sores. OraDisc is developed as an improved drug delivery system for the treatment of canker sores.
A glance at Uluru Inc. (OTCMKTS:ULUR)’s key stats reveals a current market capitalization of 4.26 Million based on 62.97 Million shares outstanding and a price at last close of $0.0677 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-03-29, Wallberg picked up 701,262 at a purchase price of $0.07. This brings their total holding to 825,519 as of the date of the filing.
On the sell side, the most recent transaction saw Oss unload 3,400,000 shares at a sale price of $0.16. This brings their total holding to 8,061,522.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Uluru Inc. (OTCMKTS:ULUR) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Lytton Laurence is Buying Catalyst Biosciences (NASDAQ:CBIO) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Catalyst Biosciences Inc. (NASDAQ:CBIO) reported that Lytton Laurence W has picked up 220,500 of common stock as of 2017-04-13.
The acquisition brings the aggregate amount owned by Lytton Laurence W to a total of 220,500 representing a 8.1% stake in the company.
For those not familiar with the company, Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.
A glance at Catalyst Biosciences Inc. (NASDAQ:CBIO)’s key stats reveals a current market capitalization of 5.00 Million based on 1.00 Million shares outstanding and a price at last close of $5.41 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-12-17, Usman picked up 4,000 at a purchase price of $2.00. This brings their total holding to 78,375 as of the date of the filing.
On the sell side, the most recent transaction saw Barris unload 1,000 shares at a sale price of $5.13. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Catalyst Biosciences Inc. (NASDAQ:CBIO) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
ConforMIS Inc. (NASDAQ:CFMS) is Attracting Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), ConforMIS Inc. (NASDAQ:CFMS) reported that Aeris Capital Archer L.p. has picked up 1,480,349 of common stock as of 2017-04-12.
The acquisition brings the aggregate amount owned by Aeris Capital Archer L.p. to a total of 1,480,349 representing a 3.4% stake in the company.
For those not familiar with the company, ConforMIS, Inc. is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints. It offers a line of customized knee implants designed to restore the natural shape of a patient’s knee. It offers iTotal CR, which is a total knee replacement implant. Its iFit technology platform consists of three elements, including iFit Design, its algorithms and computer software that is used to design customized implants and associated single-use patient-specific instrumentation referred to as iJigs, based on computed tomography scans of the patient and to prepare a surgical plan customized for the patient (iView); iFit Printing, which is a three-dimensional printing technology used to manufacture iJigs, and iFit Just-in-Time manufacturing and delivery capabilities.
A glance at ConforMIS Inc. (NASDAQ:CFMS)’s key stats reveals a current market capitalization of 223.92 Million based on 43.82 Million shares outstanding and a price at last close of $5.14 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-05-17, Law picked up 1,600 at a purchase price of $6.20. This brings their total holding to 24,793 as of the date of the filing.
On the sell side, the most recent transaction saw Steines unload 5,000 shares at a sale price of $5.00. This brings their total holding to 195,745.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on ConforMIS Inc. (NASDAQ:CFMS) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
See who picked Bellicum Pharmaceuticals (NASDAQ:BLCM)
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) reported that Baker Bros. Advisors has picked up 5,032,313 of common stock as of 2017-04-11.
The acquisition brings the aggregate amount owned by Baker Bros. Advisors to a total of 5,032,313 representing a 15.2% stake in the company.
For those not familiar with the company, Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company’s product candidates include BPX-501, BPX-601 and BPX-701. The Company’s CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.
A glance at Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM)’s key stats reveals a current market capitalization of 457.66 Million based on 32.16 Million shares outstanding and a price at last close of $12.86 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-03-24, Baker picked up 151,177 at a purchase price of $12.00. This brings their total holding to 4,527,089 as of the date of the filing.
On the sell side, the most recent transaction saw Slawin unload 30,000 shares at a sale price of $12.54. This brings their total holding to 294,982.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Eleven Biotherapeutics Inc. (NASDAQ:EBIO) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Eleven Biotherapeutics Inc. (NASDAQ:EBIO) reported that Flagship Ventures Fund 2007, L.p. has picked up 829,982 of common stock as of 2017-04-07.
The acquisition brings the aggregate amount owned by Flagship Ventures Fund 2007, L.p. to a total of 829,982 representing a 3.4% stake in the company.
For those not familiar with the company, Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).
A glance at Eleven Biotherapeutics Inc. (NASDAQ:EBIO)’s key stats reveals a current market capitalization of 47.44 Million based on 24.70 Million shares outstanding and a price at last close of $1.98 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2014-02-11, Flagship picked up 32,912 at a purchase price of $10.00. This brings their total holding to 293,268 as of the date of the filing.
On the sell side, the most recent transaction saw Mccabe unload 1,399 shares at a sale price of $2.10. This brings their total holding to 5,930.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Eleven Biotherapeutics Inc. (NASDAQ:EBIO) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Echo Therapeutics Inc. (NASDAQ:ECTE) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Echo Therapeutics Inc. (NASDAQ:ECTE) reported that Schoenbart Alan Wayne has picked up 774,500 of common stock as of 2017-04-06.
The acquisition brings the aggregate amount owned by Schoenbart Alan Wayne to a total of 774,500 representing a 5.6% stake in the company.
For those not familiar with the company, Echo Therapeutics, Inc. is a medical device company. The Company is engaged in developing a non-invasive, wireless continuous glucose monitoring (CGM) system with use in the wearable-health consumer market, diabetes outpatient market and in the hospital setting. The Company operates through the development of transdermal skin permeation and diagnostic medical devices segment. The Company has also developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, enhanced delivery of topical pharmaceuticals and other applications. The CGM System includes a skin preparation device, transdermal glucose sensor, battery and wireless transmitter. The Company has conducted several human feasibility clinical studies with its CGM System in healthy subjects, diabetics and critically ill patients, as well as a clinical study at several hospitals in the United States.
A glance at Echo Therapeutics Inc. (NASDAQ:ECTE)’s key stats reveals a current market capitalization of 1.68 Million based on 12.00 Million shares outstanding and a price at last close of $0.140 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-20-20, Schoenbart picked up 2,500 at a purchase price of $1.44. This brings their total holding to 2,500 as of the date of the filing.
On the sell side, the most recent transaction saw Young unload 10,000 shares at a sale price of $2.38. This brings their total holding to 160,874.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Echo Therapeutics Inc. (NASDAQ:ECTE) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Retractable Technologies Inc. (NYSEMKT:RVP) is Attracting Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Retractable Technologies Inc. (NYSEMKT:RVP) reported that Bml Investment Partners, L.p. has picked up 1,959,059 of common stock as of 2017-03-31.
The acquisition brings the aggregate amount owned by Bml Investment Partners, L.p. to a total of 1,959,059 representing a 6.6% stake in the company.
For those not familiar with the company, Retractable Technologies, Inc. designs, develops and manufactures safety medical products for the healthcare industry. The Company markets VanishPoint and PatientSafe products. The VanishPoint products are designed specifically to prevent needle stick injuries and to prevent reuse. The VanishPoint safety products include tuberculin, insulin and allergy antigen VanishPoint syringes; 0.5mL, 1mL, 2mL, 3mL, 5mL and 10mL VanishPoint syringes, and the VanishPoint autodisable syringe. It also sells the VanishPoint intravenous catheter, the VanishPoint blood collection tube holder and the VanishPoint blood collection set. The PatientSafe syringe reduces the risk of bloodstream infections resulting from catheter hub contamination. Its PatientSafe products include 3mL, 5mL, 10mL, 20mL, 30mL and 60mL syringes, and the PatientSafe Luer cap. Its product designs include retractable needle syringe designs, retractable needle designs and retractable needle dental syringe designs.
A glance at Retractable Technologies Inc. (NYSEMKT:RVP)’s key stats reveals a current market capitalization of 31.60 Million based on 29.65 Million shares outstanding and a price at last close of $1.08 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-01-12, Shaw picked up 2,000,000 at a purchase price of $0.89. This brings their total holding to 12,065,642 as of the date of the filing.
On the sell side, the most recent transaction saw Mack unload 100 shares at a sale price of $1.42. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Retractable Technologies Inc. (NYSEMKT:RVP) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Depomed Inc. (NASDAQ:DEPO) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Depomed Inc. (NASDAQ:DEPO) reported that Starboard Value LP has picked up 5,490,000 of common stock as of 2017-03-30.
The acquisition brings the aggregate amount owned by Starboard Value LP to a total of 5,490,000 representing a 8.8% stake in the company.
For those not familiar with the company, Depomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia. Its CAMBIA (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.
A glance at Depomed Inc. (NASDAQ:DEPO)’s key stats reveals a current market capitalization of 771.50 Million based on 62.10 Million shares outstanding and a price at last close of $12.82 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2013-05-10, Schoeneck picked up 25,000 at a purchase price of $5.11. This brings their total holding to 85,001 as of the date of the filing.
On the sell side, the most recent transaction saw Moretti unload 5,000 shares at a sale price of $20.84. This brings their total holding to 21,680.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Depomed Inc. (NASDAQ:DEPO) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.